DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices

Information source: University of Tennessee
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Contraception

Intervention: Lidocaine (Drug); Lubricant (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: University of Tennessee

Official(s) and/or principal investigator(s):
Kirk Brody, MD, Principal Investigator, Affiliation: University of Tennessee Chattanooga Department of Obstetrics and Gynecology

Overall contact:
Ben Moore, MD, Phone: 423-778-7515, Email: benatmc@hotmail.com

Summary

The hypothesis of this study is that topical cervical and intra-cervical lidocaine will decrease pain associated with the insertion of a Mirena« (levonorgestrel intrauterine device). 1. Primary Aim- Determine if topical lidocaine intra-cervically and on the cervix decreases the pain associated with insertion of a Mirena« (levonorgestrel intrauterine device).

Clinical Details

Official title: Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices

Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention

Primary outcome: Determine if topical lidocaine intra-cervically and on the cervix decreases the pain associated with insertion of a Mirena® (levonorgestrel intrauterine device).

Detailed description: There have been multiple studies performed to determine a medication that will decrease the pain associated with intrauterine device insertion. These studies have tested the use of misoprostol as well as NSAIDS to determine if these decrease the pain associated with insertion. There has also been one small, poorly performed, study that tested the use of intracervical topical lidocaine prior to IUD insertion. Misoprostol and NSAIDS were found to be non-efficacious in decreasing pain. Topical lidocaine was shown to be effective, however, secondary to this being a poorly performed study, additional studies are needed. This study is to determine if topical lidocaine does indeed decrease the pain associated with insertion of the Mirena® (levonorgestrel intrauterine device). This is a double blinded experimental study to determine whether or not topical lidocaine gel applied to the cervix and intra-cervically decreases pain associated with insertion of the Mirena® (levonorgestrel intrauterine device). Subjects will be randomized into two groups. One group will receive 2% lidocaine gel on the cervix and intra-cervically. The other group will receive a placebo, which will consist of KY being placed on the cervix and intra-cervically. After the Mirena® (levonorgestrel intrauterine device) is inserted, each subject's pain will be assessed by using a visual analog pain scale, and their response will be recorded on the information form. This pain scale will be assessed at the time of insertion, five minutes after insertion, and ten minutes after insertion. The only other study that researched the use of topical lidocaine prior to insertion of an IUD only recorded a pain scale at the time of insertion. Additional scores will be recorded at five and ten minutes to determine if pain is reduced in those time periods. These time periods have been chosen in order that all of this information can be recorded during a normal office visit. A visual analog pain scale is the scale included which measures pain on a scale of zero to ten with zero being no pain at all and ten being the worst pain of your life. This pain scale will be a scale ranging from zero to ten with faces depicting the amount of pain involved for each score. Since there will be different physicians placing the intrauterine devices, there will be a protocol on how to perform the insertion in an attempt to make all insertions as uniform as possible. A copy of this protocol has been included.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Female.

Criteria:

Inclusion Criteria: 1. Any subject receiving a Mirena® (levonorgestrel intrauterine device) for standard indications. 2. Subjects who received nonsteroidal anti-inflammatory drugs (NSAIDS) will not be excluded. Exclusion Criteria: 1. Subjects do not desire to be involved in the study 2. Subjects who have taken narcotics. 3. If the Mirena® (levonorgestrel intrauterine device) is not able to be successfully placed. 4. If cervical dilation is required, these subjects will be placed in a separate subset and will be reported on separately. 5. Subject has allergy to lidocaine.

Locations and Contacts

Ben Moore, MD, Phone: 423-778-7515, Email: benatmc@hotmail.com

University of Tennessee Chattanooga Department of Obstetrics and Gynecology, Chattanooga, Tennessee 37403, United States; Recruiting
Ben Moore, MD, Phone: 423-778-2580, Email: benatmc@hotmail.com
Brett Bryant, MD, Phone: 423-778-7515, Email: brett_bryant@hotmail.com
Kirk Brody, MD, Principal Investigator
Benjamin Moore, MD, Sub-Investigator
Joseph Bryant, MD, Sub-Investigator
David Barker, MD, Sub-Investigator
Additional Information

Starting date: August 2010
Last updated: June 15, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017